The company has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Clomipramine Hydrochloride Capsules USP in the strengths 25 mg, 50 mg, and 75 mg, Alembic Pharmaceuticals said in a regulatory filing.
Five under-valued pharma stocks to buy
These are firms with strong financials and relatively reasonable valuations
With the outbreak of the Covid-19 pandemic, investors latched on to stocks from defensive sectors such as pharmaceuticals, IT and FMCG to beat market volatility. Investors in such stocks were handsomely rewarded in 2020. Take for instance, the S&P BSE Healthcare Index that surged 97 per cent from the March low until December-end 2020.
With the economy showing definite signs of revival, also testified by the December quarter company results, cyclicals stocks are set to do well. While the pharmaceutical sector may not offer another successive year of spectacular returns, one can still search good long-term bets here.
Skip to main content
Currently Reading
An S.F. bar parklet was vandalized with message about homelessness. The bar s owners had a surprising reply
FacebookTwitterEmail
A parklet belonging to Haight-Ashbury bar The Alembic was vandalized with graffiti Thursday. Vandals also installed curtains, a welcome mat and a makeshift dining table.Alembic
A parklet belonging to Haight-Ashbury bar The Alembic was vandalized with graffiti Thursday in what the bar’s owner characterized as an unsolicited piece of street art calling attention to San Francisco’s homelessness crisis.
“The city sweeps people, but not these?” a vandal spray-painted across the exterior wall of three separate dining pods outside the Haight Street bar. The vandal also installed pink curtains, a television, a welcome mat and a makeshift table set with dried flowers and a salt shaker.
The sector that had peaked out on the bourses in 2015 saw buying interest due to the focus on healthcare. However, the interest is likely to wane as Covid recedes.
Indian pharma grows for 5th straight month; sales rise 4.5% in January
Growth in the Indian pharma market is expected to be linear ahead. The market has now grown for the fifth consecutive month and the momentum is likely to improve
Niti Kiran | February 14, 2021 | Updated 12:54 IST
The Indian pharmaceutical market s (IPM) maintained its growth trajectory for the fifth consecutive month by expanding 4.5 per cent in January. After growing 8.5 per cent in December, it grew 4.5 per cent last month, signalling that the post-Covid recovery is in full swing, pointed an Anand Rathi report.
Listed pharma companies that drove growth were Ajanta which grew 16 per cent, JB Chemicals (13.5 per cent), Ipca (12.5 per cent), Alkem (9.3 per cent) and Zydus Cadila (8.1 per cent). However, a few reported declines sales of Natco were down 38.4 per cent, Indoco (down 5.1 per cent), Alembic (down 3.6 per cent) and FDC (down 2.7 per cent).